Aspectos epidemiológicos das doenças intestinais inflamatórias na macrorregião de saúde leste do Estado de Minas Gerais

Oliveira, Flávia Márcia; Emerick, Ana Paula do Carmo; Soares, Elisângela Guimarães

doi:10.1590/s1413-81232010000700009

Cited by 21 publications

(22 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The Montreal classification, owing to its diagnostic and therapeutic implications, has been increasingly used in patients with CD. In most studies related to classification according to location, the ileocolonic type was the most frequent, followed by the ileal and colonic types (2)(3)(4)(5)(6)(8)(9)(10)12,14) . In this study, patients with CD showed a higher prevalence of the ileocolonic type (L3), corroborating the results of recent multicenter studies that included countries in Europe, North America, and Oceania (2) .…”

Section: Discussionmentioning

confidence: 99%

“…In Brazil, patients with CD and UC are not necessarily reported resulting in a lack of epidemiologic data with respect to these diseases. This situation places patients in a vulnerable state, as incipient studies and the poor publication records on this group of diseases contribute to their late diagnosis and increased morbidity (3,4,6,8,9,14) . It is difficult to determine the epidemiologic data of IBD in Brazil and all developing countries owing to deficiencies in data recording systems and the inability to access data other than those in the public health system.…”

Section: Introductionmentioning

confidence: 99%

“…It is difficult to determine the epidemiologic data of IBD in Brazil and all developing countries owing to deficiencies in data recording systems and the inability to access data other than those in the public health system. Given this reality, specialty pharmacies and reference centers for the treatment of IBD are favorable places for performing IBD-related studies (6,8,9,14) . The outpatient follow-up of patients with IBD aims to control symptoms and induce disease remission, adapt patients to their chronic condition and improve their quality of life, minimize toxicity and monitor the adverse effects of prescribed drugs, and postpone or reduce the incidence of relapse (1) .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Inflammatory Bowel Disease: Outpatient Treatment Profile

Santos

Carvalho

Silva

et al. 2017

Arq. Gastroenterol.

View full text Add to dashboard Cite

-Background -Crohn's disease and ulcerative colitis are the two major forms of inflammatory bowel disease. The incidence and prevalence of both conditions have increased and are progressively increasing. These diseases are frequently recurrent and clinically highly severe. In Brazil, the lack of epidemiological data related to such diseases has left these patients in a vulnerable state and contributed to increased morbidity. Objective -To describe the profiles of patients with inflammatory bowel disease treated in an outpatient service in Brazil. Methods -This descriptive, exploratory, and retrospective documentary study with a quantitative approach was performed in an outpatient treatment service for inflammatory bowel disease, at a university polyclinic located in Rio de Janeiro, Brazil, from May to July 2016. The study included 556 patients and was approved by the research ethics committee of the institution (CAAE no. 55179316.6.0000.5259/2016). Results -The data showed a high prevalence of inflammatory bowel disease in white female patients. Crohn's disease was diagnosed in more patients than was ulcerative colitis; the ileocolon was the most commonly affected location in patients with Crohn's disease. The stenotic phenotype was prevalent in patients with Crohn's disease. Conclusion -The prevalence of the stenotic phenotype in Crohn's disease in relation to others demonstrates the need for further investigations in this field of study in Brazil. In conclusion, the data showed that the epidemiologic profile of the study population is similar to that published in the national and international literature. HEADINGS -Inflammatory bowel diseases. Crohn disease. Ulcerative colitis. Epidemiology.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Inflammatory Bowel Disease: Outpatient Treatment Profile

Santos

Carvalho

Silva

et al. 2017

Arq. Gastroenterol.

View full text Add to dashboard Cite

show abstract

“…The recurrent and chronic inflammation of the intestinal mucosa leads to the emergence of Inflammatory Bowel Diseases (IBD), such as ulcerative colitis. These diseases lead to clinical signs and symptoms, such as diarrhea with blood and/or mucus, weight loss, increased bowel movements, nausea, vomiting, and abdominal pain [ 3 , 4 ]. Ulcerative colitis is generally related to the cecum, colon, and rectum regions, and its histological changes are limited to the mucosa [ 3 , 4 ].…”

Section: Introductionmentioning

confidence: 99%

The Bisindole Alkaloid Caulerpin, from Seaweeds of the Genus Caulerpa, Attenuated Colon Damage in Murine Colitis Model

et al. 2018

View full text Add to dashboard Cite

Caulerpin (CLP), an alkaloid from algae of the genus Caulerpa, has shown anti-inflammatory activity. Therefore, this study aimed to analyze the effect of CLP in the murine model of peritonitis and ulcerative colitis. Firstly, the mice were submitted to peritonitis to evaluate which dose of CLP (40, 4, or 0.4 mg/kg) could decrease the inflammatory infiltration in the peritoneum. The most effective doses were 40 and 4 mg/kg. Then, C57BL/6 mice were submitted to colitis development with 3% dextran sulfate sodium (DSS) and treated with CLP at doses of 40 and 4 mg/kg. The disease development was analyzed through the disease activity index (DAI); furthermore, colonic tissue samples were submitted to histological analysis, NFκB determination, and in vitro culture for cytokines assay. Therefore, CLP at 4 mg/kg presented the best results, triggering improvement of DAI and attenuating the colon shortening and damage. This dose was able to reduce the TNF-α, IFN-γ, IL-6, IL-17, and NFκB p65 levels, and increased the levels of IL-10 in the colon tissue. Thus, CLP mice treatment at a dose of 4 mg/kg showed promising results in ameliorating the damage observed in the ulcerative colitis.

show abstract

“…Apesar disso, podese considerar que há, em nosso país, uma baixa incidência e prevalência de DII (Souza et al, 2008). Segundo Oliveira et al (2010), houve, no entanto, um aumento considerável nos casos de CD e UC no Sudeste do Brasil, conforme o levantamento realizado junto ao Hospital Universitário da Faculdade de Medicina de Ribeirão Preto (SP -Brasil).…”

Section: Aspectos Epidemiológicos Da Doença Inflamatória Intestinalunclassified

Emprego de terapia celular em modelo experimental de doença inflamatória intestinal.

Marcelino¹

View full text Add to dashboard Cite

(DII) é um estado patológico crônico, recidivante, que acomete o trato gastrointestinal. Incluem-se no espectro da DII duas entidades nosológicas: a Colite Ulcerativa e a Doença de Crohn. A colite é uma doença caracterizada pela inflamação difusa da mucosa do cólon. Afeta o reto (95% dos casos) e as porções proximais do cólon, de maneira simétrica e contínua, ou seja, não há áreas de mucosas normais entre as partes afetadas. Apesar da existência de terapias para melhora dos sintomas, não há nenhum tratamento curativo. O tratamento cirúrgico envolve procedimentos complexos associados a altas taxas de morbimortalidade. Neste contexto, a terapia celular (TC) com células-tronco (CT) desponta como uma nova opção de tratamento. Pretendeu-se, no presente estudo, verificar a segurança e a eficácia do transplante de células-tronco derivadas do tecido adiposo (ASC) em ratos com colite ulcerativa induzida por ácido trinitrobenzenosulfonico (TNBS). A população celular foi isolada do tecido adiposo, da região inguinal de ratos, por dissociação mecânica e cultivada na presença de Alpha-Mem (Minimum Essential Medium Eagle Alpha Modification), soro bovino fetal e antibiótico/antimicótico. O comportamento celular foi verificado por meio da morfologia, proliferação, viabilidade, capacidade de aderência à superfície plástica e parâmetros de diferenciação osteogênica, condrogênica e adipogênica. Os animais foram avaliados, considerando-se os aspectos clínicos (presença de diarréia, consumo de alimento e peso corporal), macroscópicos (escore e extensão da lesão, relação peso/comprimento do cólon, aderência a órgãos adjacentes), microscópicos e bioquímicos (determinação do conteúdo de glutationa total e da atividade enzimática da mieloperoxidase). No modelo experimental de colite ulcerativa, a infusão de ASC reduziu significativamente a presença de aderências entre o cólon e órgãos adjacentes, bem como diminuiu a quantidade de células inflamatórias na mucosa lesada. Conclui-se que as ASC podem promover e/ou acelerar o processo de regeneração da mucosa intestinal inflamada e assim, serem empregadas como uma opção terapêutica com amplo potencial de aplicabilidade no tratamento da DII. Palavras-chave: Células-tronco derivadas do tecido adiposo. Terapia celular. Doença inflamatória intestinal. Colite ulcerativa.

show abstract

Aspectos epidemiológicos das doenças intestinais inflamatórias na macrorregião de saúde leste do Estado de Minas Gerais

Abstract: Aspectos epidemiológicos das doenças intestinais inflamatórias na macrorregião de saúde leste do Estado de Minas Gerais

Cited by 21 publications

References 23 publications

Inflammatory Bowel Disease: Outpatient Treatment Profile

Inflammatory Bowel Disease: Outpatient Treatment Profile

The Bisindole Alkaloid Caulerpin, from Seaweeds of the Genus Caulerpa, Attenuated Colon Damage in Murine Colitis Model

Emprego de terapia celular em modelo experimental de doença inflamatória intestinal.

Contact Info

Product

Resources

About